{'fraction_non_alphanumeric': 0.03770491803278689, 'fraction_numerical': 0.03770491803278689, 'mean_word_length': 6.104651162790698, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Improved efficacy of α‐particle–targeted radiation therapy

Human epidermal growth factor receptor–2 (HER‐2) and tumor‐associated glycoprotein 72 (TAG‐72) have proven to be excellent molecular targets for cancer imaging and therapy. Trastuzumab, which binds to HER‐2, is effective in the treatment of disseminated intraperitoneal disease when labeled with 213Bi or 212Pb. 213Bi‐humanized CC49 monoclonal antibody (HuCC49ΔCH2), which binds to TAG‐72, inhibits the growth of subcutaneous xenografts. A next logical step to improve therapeutic benefit would be to target tumors with both molecules simultaneously.